Business
Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting
Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n - Data from a phase 1b, investigator-sponsored study show that a pelareorep-based combination therapy is safe and well-tolerated in newly diagnosed glioblastoma multiforme patients\n \n \n Canada NewsWire\n \n \n SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2020\n \n \n \n \n \n SAN DIEGO, CA\n \n and\n \n CALGARY, AB\n \n ,\n \n Nov. 9, 2020\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. [NASDAQ: ONCY] [TSX: ONC] today announced the publication of an abstract for an oral presentation to be given as part of the virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting. The abstract highlights clinical data from ReoGlio, an investigator-sponsored phase\n \n 1b\n \n trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM). For more details on the abstract and the oral presentation, see below.\n \n \n \n Abstract ID:\n \n CTIM-14\n \n \n \n Title:\n \n Pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) with standard chemoradiotherapy/adjuvant temozolomide for glioblastoma multiforme (GBM) patients: ReoGlio phase I trial results.\n \n \n \n Session Name:\n \n Clinical Trials Session II\n \n \n \n Presentation Date and Time:\n \n On-demand (\n \n link\n \n to the presentation)\n \n \n \n Speaker:\n \n \n Susan Short\n \n , M.R.C.P., Ph.D., Professor of Clinical Oncology and Neuro-Oncology at the University of Leeds\n \n \n The published abstract is available on the SNO website at\n \n https://academic.oup.com/neuro-oncology\n \n .\n \n \n \n About ReoGlio\n \n \n \n The ReoGlio trial was an investigator-sponsored, phase\n \n 1b\n \n , open-label trial evaluating the combination of pelareorep and GM-CSF, alongside standard chemoradiotherapy and a...